



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

A GWAS sequence variant for platelet volume marks an alternative DNM3 promoter in megakaryocytes near a MEIS1 binding site

Citation for published version:

Nürnberg, ST, Rendon, A, Smethurst, PA, Paul, DS, Voss, K, Thon, JN, Lloyd-Jones, H, Sambrook, JG, Tijssen, MR, Italiano, JE, Deloukas, P, Gottgens, B, Soranzo, N, Ouwehand, WH, HaemGen Consortium & Pirastu, N 2012, 'A GWAS sequence variant for platelet volume marks an alternative DNM3 promoter in megakaryocytes near a MEIS1 binding site' *Blood*, vol 120, no. 24, pp. 4859-68. DOI: 10.1182/blood-2012-01-401893

Digital Object Identifier (DOI):

[10.1182/blood-2012-01-401893](https://doi.org/10.1182/blood-2012-01-401893)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Blood

Publisher Rights Statement:

© 2012 by The American Society of Hematology

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



blood

2012 120: 4859-4868
Prepublished online September 12, 2012;
doi:10.1182/blood-2012-01-401893

A GWAS sequence variant for platelet volume marks an alternative *DNM3* promoter in megakaryocytes near a *MEIS1* binding site

Sylvia T. Nürnberg, Augusto Rendon, Peter A. Smethurst, Dirk S. Paul, Katrin Voss, Jonathan N. Thon, Heather Lloyd-Jones, Jennifer G. Sambrook, Marloes R. Tijssen, the HaemGen Consortium, Joseph E. Italiano Jr, Panos Deloukas, Berthold Gottgens, Nicole Soranzo and Willem H. Ouwehand

Updated information and services can be found at:

<http://bloodjournal.hematologylibrary.org/content/120/24/4859.full.html>

Articles on similar topics can be found in the following Blood collections

[Platelets and Thrombopoiesis](#) (436 articles)

Information about reproducing this article in parts or in its entirety may be found online at:

http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:

<http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:

<http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml>

Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.

Copyright 2011 by The American Society of Hematology; all rights reserved.



A GWAS sequence variant for platelet volume marks an alternative *DNM3* promoter in megakaryocytes near a *MEIS1* binding site

*Sylvia T. Nürnberg,¹ *Augusto Rendon,^{1,2} Peter A. Smethurst,¹ Dirk S. Paul,³ Katrin Voss,¹ Jonathan N. Thon,^{4,5} Heather Lloyd-Jones,¹ Jennifer G. Sambrook,¹ Marloes R. Tijssen,^{1,6} the HaemGen Consortium, Joseph E. Italiano Jr,^{4,7} Panos Deloukas,³ Berthold Gottgens,⁶ Nicole Soranzo,³ and Willem H. Ouwehand^{1,3}

¹Department of Haematology, University of Cambridge and National Health Service Blood and Transplant, Cambridge, United Kingdom; ²Biostatistics Unit, Medical Research Council, Cambridge, United Kingdom; ³Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom; ⁴Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA; ⁵Harvard Medical School, Boston, MA; ⁶Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom; and ⁷Vascular Biology Program, Department of Surgery, Children's Hospital, Boston, MA

We recently identified 68 genomic loci where common sequence variants are associated with platelet count and volume. Platelets are formed in the bone marrow by megakaryocytes, which are derived from hematopoietic stem cells by a process mainly controlled by transcription factors. The homeobox transcription factor *MEIS1* is uniquely transcribed in

megakaryocytes and not in the other lineage-committed blood cells. By ChIP-seq, we show that 5 of the 68 loci pinpoint a *MEIS1* binding event within a group of 252 MK-overexpressed genes. In one such locus in *DNM3*, regulating platelet volume, the *MEIS1* binding site falls within a region acting as an alternative promoter that is solely used in megakaryocytes,

where allelic variation dictates different levels of a shorter transcript. The importance of dynamin activity to the latter stages of thrombopoiesis was confirmed by the observation that the inhibitor Dynasore reduced murine proplatelet formation in vitro. (*Blood*. 2012;120(24):4859-4868)

Introduction

A genome-wide association meta-analysis study (GWAS) in nearly 67 000 persons identified 68 independent loci associated with the mean platelet volume (MPV) and the count of platelets (PLT) at genome-wide (GW) significance, representing an ideal resource to make discoveries in megakaryocyte (MK) and PLT biology.¹ Although such GWASs unequivocally identified loci that are implicated in the formation and survival of PLTs, to confirm which genetic variants are responsible for the observed associations and which genes mediate their effects remains a challenge. Strategies to prioritize functional follow-up studies are therefore highly desired. Fifteen of the 68 loci are likely to act through nonsynonymous variants. The remaining 53 loci have potential roles in altering transcriptional regulation. Indeed, at one of the MPV loci at chromosome 7q22.3, we recently showed that the minor allele of the noncoding variant rs342293 disrupts a binding site of the transcription factor *EVII/MECOM*, leading to a higher transcript level of the downstream gene *PIK3CG*.²

Here we present a strategy to prioritize the functional follow-up of GWAS hits whereby sentinel single nucleotide polymorphisms (SNPs; those with the lowest *P* value at an associated locus) and those in strong linkage disequilibrium ($r^2 > 0.8$ in Europeans; proxy SNPs hereafter) are overlapped with the GW DNA binding patterns of a lineage restricted transcription factor as determined experimentally by ChIP combined with deep sequencing (ChIP-seq). This strategy has the advantage of providing hypotheses about the underlying genetic mechanisms behind the

observed associations that can be readily followed. We selected the transcription factor *MEIS1* for several reasons. First, this 3 amino acid loop extension homeodomain protein was identified as a common viral integration site in myeloid leukemias of BXH-2 mice³ and has since been established as a strong regulator of hematopoiesis and myeloid leukemogenesis.⁴⁻⁷ Second, *MEIS1* is exclusively transcribed in hematopoietic stem/progenitor cells and in the MK lineage; therefore, *MEIS1* binding events are highly likely to be critical for the identity of this lineage.^{8,9} Third, gene knockout in mice results in early embryonic lethality with a complete lack of megakaryopoiesis,^{10,11} and knockdown studies of *meis1* in zebrafish showed major effects on both hematopoiesis and vasculogenesis, confirming the abrogation of the formation of thrombocytes, the fish equivalent of MKs and PLTs.^{12,13} Finally, little is known about how *MEIS1* regulates megakaryopoiesis, resulting in these striking phenotypes.

In this study, we report on the successful identification of a set of *MEIS1*-regulated genes by ChIP-seq in megakaryocytic cells. The set is significantly enriched for genes implicated in megakaryopoiesis and PLT function and contains, as postulated, more PLT GWAS loci than to be expected by chance. Detailed functional studies of a dynamin isoform *DNM3*, one of the identified GWAS loci that colocalizes with a binding event, revealed that *MEIS1* binds a novel promoter that is uniquely used in the megakaryocytic lineage and where the promoter activity displays differential allelic

Submitted January 3, 2012; accepted August 28, 2012. Prepublished online as Blood First Edition paper, September 12, 2012; DOI 10.1182/blood-2012-01-401893.

*S.T.N. and A.R. contributed equally to this study.

There is an Inside *Blood* commentary on this article in this issue.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2012 by The American Society of Hematology

effects at the putative functional variant. We show that the formation of pro-PLTs from murine *in vitro*-derived MK was inhibited by the dynamin inhibitor Dynasore, confirming the importance of dynamin activity to the late stages of megakaryopoiesis.

Methods

Cell culture

CHRF 288-11 cells¹⁴ (hereafter CHRF cells) were cultured in RPMI 1640 (Sigma-Aldrich), 10% FBS (Invitrogen), and 200 μ M L-glutamine, 100 U penicillin, and 100 μ g/mL streptomycin (Sigma-Aldrich). The 1603MED cells¹⁵ were cultured in DMEM, high glucose, with sodium pyruvate, without L-glutamine (PAA Laboratories), and supplemented with 10% FBS, 1% nonessential amino acids (HyClone, Thermo Scientific), and 200 μ M L-glutamine, 100 U/mL penicillin, and 100 μ g/mL streptomycin.

MK culture

MKs were obtained by culture of CD34⁺ hematopoietic progenitor cells as previously reported.¹⁶ In short, cord blood was collected with informed consent, and CD34⁺ cells were prepared by magnetic bead selection. Purified cells were cultured (1×10^5 cells/mL) for up to 12 days in serum-free medium supplemented with human thrombopoietin and IL-1 β to differentiate into MKs. Cells were also harvested at days 3, 5, 7, 9, 10, and 12 and characterized by immunophenotyping with monoclonal antibodies against relevant CD markers and by analysis of RNA on Illumina whole genome expression arrays.¹ By day 10, > 90% of cells stained positive for CD41 and negative for CD34.

ChIP and massive parallel sequencing

Twenty million CHRF cells per condition were crosslinked for 10 minutes with 1% formaldehyde. Cells were lysed for 10 minutes on ice (10mM Tris, pH 8.0, 10mM NaCl, 0.2% NP-40). Nuclei were then lysed for 10 minutes on ice (50mM Tris, pH 8.1, 10mM EDTA, 1% SDS). Crosslinked chromatin was sheared for 2×5 minutes by sonication using a Bioruptor (Diagenode) and precleared with 100 μ g anti-rabbit IgG preimmune serum (Sigma-Aldrich) using protein G-Sepharose beads (Roche Diagnostics). ChIP was performed overnight in IP dilution buffer (20mM Tris, pH 8.1, 2mM EDTA, 150mM NaCl, 1% Triton X-100, 0.01% SDS), using 14 μ g anti-MEIS1 (Abcam, ab19867, lot no. 153899) or anti-rabbit IgG (Sigma-Aldrich I5006, lot no. 115K7551), respectively. Beads were washed twice with buffer 1 (20mM Tris, pH 8.1, 2mM EDTA, 50mM NaCl, 1% Triton X100, 0.1% SDS), once with buffer 2 (10mM Tris, pH 8.1, 1mM EDTA, 250mM LiCl, 1% NP40, 1% sodium deoxycholate monohydrate), and twice with TE (10mM Tris, 1mM EDTA, pH 8.0) buffer. Bound chromatin was eluted from the beads twice with 100mM NaHCO₃ containing 1% SDS. After reverse crosslinking and RNaseA and proteinase K digestion, chromatin was cleaned up using the QIAGEN PCR purification kit (QIAGEN). ChIP-seq library generation, cluster formation, and sequencing were performed at the Michael Smith Genome Sciences Center (Vancouver, BC) on an Illumina GAI analyzer. The resulting 9 513 449 single-end reads were mapped to the human genome (hg19) using stampy 1.0.11_(r880).¹⁷ Of the reads, 7 323 093 were of high mapping quality (> 30). Peaks were called using MACS¹⁸ and PICS.¹⁹ Peak overlap was generated by requiring a minimum overlap of 150 nucleotides. Results were deposited at ArrayExpress (www.ebi.ac.uk/arrayexpress/) under accession number *E-MTAB-859*.

Overlap with GWAS loci and significance analysis

For each of the 68 associated loci, candidate functional SNPs were selected by identifying all single nucleotide variants with an $r^2 > 0.8$ and within 100 kb of the sentinel SNP in the European samples of the 1000 Genomes project (June 2011 release). To establish whether the association of a locus could potentially be of regulatory origin, we determined whether at least one candidate functional SNP overlapped with a ChIP-seq peak. Because

the chance of identifying an overlap between a sentinel SNP and a MEIS1 binding peak is sensitive to the number of peaks considered, the overlap analysis was carried by successively increasing the number of peaks by including peaks with decreasing peak height. We estimated the significance of observing a given number of overlaps by resampling. A total of 50 000 sets of 66 loci (2 GWAS SNPs in the HLA locus were removed because of its complicated haplotype structure) were drawn from the same SNPs onto which the GWAS data were imputed (~ 2.5 million SNPs from HapMap2)²⁰ while preserving the distribution of allele frequencies. All analyses were carried out in the R/Bioconductor environment.

Functional analysis of MEIS1 binding sites

To identify annotated protein coding genes enriched in the proximity of MEIS1 binding sites, the set of 13 842 peaks jointly called by 2 algorithms was analyzed using the GREAT software (Version 1.8.1).²¹ Enrichment was tested against the whole human genome (hg19) using standard parameters. Significance was measured by binomial *P* values and the false discovery rate *q* values. In addition, a set of 1285 protein coding genes with MEIS1 binding sites located within an annotated gene body, including 5 kb each upstream and downstream, was tested for over-representation of Gene Ontology terms using FatiGO as part of the Babelomics Version 4.2 environment.²² Enrichment was tested compared with the rest of the human genome. Adjusted *P* values stem from the Fisher exact test, after correcting for multiple testing, using the false discovery rate procedure of Benjamini and Hochberg.²³

RNA sequencing

Total RNA from 10 day cultured MKs was obtained by the Trizol method as described.¹⁶ Polyadenylated RNA was purified from this by 2 rounds of magnetic Oligo dT25 selection (Dynabeads Oligo (dT)25, Invitrogen) in the presence of RNase inhibitor (New England Biolabs), combined with DNase treatment (Ambion, Invitrogen). The mRNA was fragmented using RNA fragmentation reagent (Ambion, Invitrogen) and precipitated with added glycogen (Ambion), then cDNA produced by Superscript Double Stranded cDNA synthesis kit (Invitrogen), replacing oligo-dT primer with random primer. Thereafter, library preparation was as per mRNA-sequencing kit (Illumina), starting with end repair. Bands of ~ 300-450 bp were gel extracted for paired-end sequencing by Illumina GAI analyzer with a read length of 76 bp. The RNA-seq results are deposited at ArrayExpress under accession number *E-MTAB-918*.

FAIRE

Formaldehyde-assisted isolation of regulatory elements (FAIRE) experiments were carried out as previously described.²⁴ In short, 20 million cells were cross-linked with 1% formaldehyde for 12 minutes and subjected to 12 sonication cycles using the Bioruptor UCD-200. The sample was cleaned-up using the MinElute PCR Purification Kit (QIAGEN). FAIRE DNA was processed following the Illumina paired-end library generation protocol. The genomic libraries were sequenced at 54-bp paired-end reads on an Illumina GAI analyzer. Sequence reads were aligned to the human genome (hg19) using stampy 1.0.11_(r880) with default parameters. The FAIRE-seq data are deposited at ArrayExpress under accession number *E-MTAB-858*.

MPV

EDTA anticoagulated blood from volunteers of the Cambridge BioResource (<http://www.cambridgebioresource.org.uk>) was obtained with informed consent under the Cardoso Project: Genes and Mechanisms in Cardiovascular Disease. Ethical approval for this study, conducted in accordance with the Declaration of Helsinki, was given by the Cambridgeshire 1 Research Ethics Committee. Full blood counts, including the measurement of MPVs, were obtained from blood samples within 2 hours after collection using a Coulter LH500 hematology analyzer (Beckman-Coulter).

Platelet isolation

Citrate anticoagulated samples of blood were obtained from Cambridge BioResource volunteers and centrifuged for 20 minutes at 150g to obtain

PLT-rich plasma (PRP). The PRP was centrifuged twice more, each time retaining the supernatant and discarding the leukocyte-rich pellet together with the 0.5-mL PRP layer immediately above it. The PRP was further leukocyte-depleted by mixing with anti-CD45 magnetic beads (Dynabeads CD45, Invitrogen; 33 μ L beads/mL of PRP) and rotating at room temperature for 20 minutes. The beads were removed by Dynal MPC-L magnet, using 2 cycles of 2-minute magnetization steps and transferring the PRP to fresh tubes after each step. The leukocyte-depleted PRP was centrifuged for 10 minutes at 1500g. The supernatant was discarded and the PLT pellet resuspended in 2 mL Trizol (Invitrogen) until a particle-free solution was obtained; 1-mL aliquots were frozen on dry ice and stored at -80°C . Starting PRP volumes ranged from 5 to 15 mL, and corresponding yields ranged from 0.5 to 2.5×10^9 PLTs.

RNA preparation and cDNA synthesis

RNA from cultured cells and PLTs was prepared using Trizol essentially according to the manufacturer's instructions, except that 2-mL Phase Lock Gel tubes (5') were used for the phase separation. RNA pellets were air dried for no more than 7 minutes and then resuspended in 15 μ L nuclease-free water (Ambion, Invitrogen). RNA yields averaged 940 ng/ 10^9 PLTs with A260/280 ratios between 1.33 and 1.66. The 25-ng PLT RNA was processed by the ABI TaqMan Reverse Transcription Reagents (Applied Biosystems) in a 25- μ L volume, according to the manufacturer's protocol. At the end of the reaction, RNA was diluted to 250 μ L with nuclease-free water and stored at -20°C . In addition, total RNA from human brain (P/N #54005, 54007, and 540117) was obtained from Stratagene (Agilent Technologies).

Gene expression quantitative real-time PCR

Absolute quantification of *DNM3* transcript abundance in RNA samples from human PLTs and other cells was carried out on a ABI Prism 7900HT Sequence Detection System (Applied Biosystems) using the following protocol: 50°C 2 minutes, 95°C 10 minutes, $40 \times (95^{\circ}\text{C}$ 15 seconds, 60°C 1 minute). Product numbers of the used TaqMan gene expression assays (Applied Biosystems) can be found in supplemental Table 1 (available on the *Blood* Web site; see the Supplemental Materials link at the top of the online article). To test for abundance of the novel *DNM3* transcript variant, a custom TaqMan assay was designed with the probe spanning the boundary between the novel exon 2B and exon 3. Transcript levels were normalized to *GAPDH*. Reactions were measured in triplicate and primer efficiencies obtained through cDNA standard dilution series.

RACE

5'-Rapid amplification of cDNA ends (RACE) on RNA samples from CHRF and MK cells and PLTs was performed using the 5'/3' RACE Kit, 2nd Generation (Roche Diagnostics) following the manufacturer's protocol. For the PCR amplification steps, recombinant Taq polymerase and dNTPs from Fermentas were used (Fermentas). DNA fragments were subcloned into pGem T easy (Promega) and sequenced. Primer and clone sequences can be found in supplemental Table 2.

Dual Luciferase reporter assays

DNA fragments were cloned into the firefly Luciferase vector pGI4.10 (Promega). Ten million cells were transfected with 10 μ g firefly Luciferase vector and 500 ng Renilla Luciferase vector pGI4.74 (Promega). Transfection was performed via electroporation using a Bio-Rad GenePulser Xcell (exponential curve, 220 V, 900 μ F, resistance ∞ , 4-mm cuvettes). Luciferase activity was measured in a LUMIstar Optima luminometer (BMG Labtech) using the Dual-Luciferase Reporter Assay kit (Promega). Random DNA sequences for use as negative controls were generated by the Random DNA Sequence Generator (<http://www.faculty.ucr.edu/~mmaduro/random.htm>) and produced by artificial gene synthesis (GeneArt). For sequences of cloning primers and construct inserts, see supplemental Table 3.

Electrophoretic mobility shift assay

See supplemental Methods.

MK suspension cultures

Mouse fetal liver cells were collected from WT CD1 mice (Charles River Laboratories) on day E13.5 and cultured at 37°C and 5% CO_2 in the presence of 0.1 μ g/mL purified recombinant mouse c-Mpl ligand for 5 days. Fetal liver cell cultures were layered on a single-step gradient (1.5%-3.0% BSA) on culture day 4, and MKs were allowed to sediment for 30 minutes.²⁵ The MK pellet was then resuspended in fresh media and cultured for an additional 24 hours alone or in the presence of either 0.3% DMSO or 100 μ M DynaSore in DMSO. MK cultures were examined on day 5 by phase-contrast microscopy using a Nikon eclipse TS100 benchtop microscope (Nikon) at $20\times$ magnification; digital images were collected on a Hamamatsu C2400 CCD camera and analyzed using ImageJ. Mature MKs were identified by size ($> 10\mu\text{m}$ diameter) and distinguished from pro-PLT-producing MKs because of the presence or absence of long pro-PLT elongations (circularity ≥ 0.7). Samples were examined in triplicate, and at least 78 cells were counted for each condition tested. All studies complied with institutional guidelines approved by the Children's Hospital animal care and use committee, and the Institutional Animal Care and Use Committee.

Statistical analysis

Results are expressed as mean \pm SD with number of experiments. Statistical comparisons between groups were performed by 2-tailed *t* test using Prism unless stated otherwise. Statistical comparisons of Luciferase data were performed on log transformed signal intensities using mixed linear models to account for the hierarchical nature of the data.

Results

MEIS1 putatively regulated genes are important determinants of the PLT lineage

The expression of *MEIS1* is restricted to the megakaryocytic lineage, among differentiated blood cells (supplemental Figure 1).^{8,9} To map *MEIS1* binding events, we performed ChIP-seq in the human megakaryocytic cell line CHRF, a close model for MKs based on its transcriptional profile (supplemental Figure 2). *MEIS1* peaks were called using magnetic-activated cell sorting¹⁸ and PICS¹⁹ from which a high-confidence dataset of 13 842 binding events detected by both algorithms was generated (Figure 1A). Genes nearby *MEIS1* binding events were analyzed with GREAT²¹ (Genomic Regions Enrichment of Annotations Tool), revealing that putatively regulated genes are significantly over-represented in megakaryopoiesis and PLT biology categories (Table 1; supplemental Figure 3). To increase stringency in assigning putatively regulated genes, a list of 1285 potentially *MEIS1*-regulated genes was generated by filtering for peaks with a minimum height of 30 reads (80th percentile of peak height) and within ± 5 kb of protein coding genes (supplemental Methods). Analysis of their expression patterns showed a significant over-representation of 57 genes of a set of 252 that were shown to be strongly overexpressed in MKs relative to the other 7 mature blood cell types ($P < 5 \times 10^{-19}$; Figure 1B) in the HaemAtlas compendium of blood cell transcripts.⁸ These observations are consistent with our hypothesis that *MEIS1*, because of its characteristic lineage restriction, regulates many genes critical to the identity of MKs and PLTs. Indeed, these 57 genes contain many well-known regulators of their function, such as the collagen signaling receptor GlycoProtein (GP) VI (*GP6*), 1 of the 4 subunits of the PLT receptor for von Willebrand Factor, GPV (*GP5*), and the α granule membrane protein P-selectin (*SELP*).

A

Total reads	9513449
Peaks (MACS)	19583
Peaks (PICS)	21834
Overlap	13842
Thereof promoter	664
genomic	6472
intergenic	6706





Figure 1. MEIS1 ChIP-seq identifies genes regulating MK and PLT biology. (A) MEIS1 ChIP-seq in CHR9 288-11 cells identifies mainly intronic and intergenic binding sites. (B) Cellular functions of 57 genes with MEIS1 binding events and overexpressed in MKs. Bold represents 6 loci containing sentinel SNPs associated with MPV or PLT count.

B



MEIS1 binding profile aids in the prioritization of functional studies of GWAS loci

Six of the 57 MK overexpressed genes with a MEIS1 binding site (Figure 1B genes labeled in bold) harbored a sentinel GWAS SNP. Importantly, a GW analysis of the spatial co-occurrence of MEIS1

binding peaks with 66 sentinel SNPs (2 GWAS SNPs in the HLA locus were removed because of its complicated haplotype structure) for PLT volume and count and their proxy SNPs robustly identified at least 5 sites of colocalization when only the top 20% of MEIS1 peaks was considered (Figure 2A). Such degree of overlap was significantly greater than expected by chance ($P < 1 \times 10^{-5}$).

Table 1. Functional assessment of MEIS1 binding sites by GREAT shows enrichment of megakaryocyte and platelet phenotypes

Enriched term	Noncorrected P	FDR adjusted q
Mouse phenotype		
Abnormal platelet physiology	6.5×10^{-30}	7.3×10^{-28}
Abnormal platelet activation	4.3×10^{-22}	3.3×10^{-20}
Abnormal platelet aggregation	1.1×10^{-21}	7.8×10^{-20}
Decreased platelet aggregation	6.6×10^{-20}	4.1×10^{-18}
Abnormal vascular branching morphogenesis	1.0×10^{-19}	6.0×10^{-18}
Increased bleeding time	7.3×10^{-19}	4.0×10^{-17}
Decreased common myeloid progenitor cell number	3.9×10^{-14}	1.4×10^{-12}
Abnormal bone marrow development	6.4×10^{-8}	1.2×10^{-6}
MSigDB pathway		
Pertussis toxin-insensitive CCR5 signaling in macrophage	4.6×10^{-13}	5.1×10^{-11}
TPO signaling pathway	1.5×10^{-9}	4.5×10^{-8}
MSigDB perturbation		
Genes essential to the development of megakaryocytes, as expressed in normal cells and essential thrombocythemic cells	1.7×10^{-22}	2.4×10^{-20}


FDR indicates false discovery rate; MSigDB, molecular signatures database; and TPO, thrombopoietin (the principal growth factor for megakaryocytes).

To investigate the consequences of the observed colocalization, we selected the *DNM3* locus because the locus is strongly associated with MPV (sentinel SNP rs10914144 $P = 1.11 \times 10^{-24}$), and there are no other genes localized in the recombination interval that harbors this variant. The sentinel SNP (minor allele frequency in Europeans 0.173; 2.99% of persons are homozygous for the minor allele) is noncoding, and no coding proxy SNPs could be identified in the 1000 Genomes project catalog.²⁶ Moreover, whereas *DNM2* is ubiquitously expressed, *DNM1* and *DNM3* show tissue-specific expression profiles,^{27,28} whereby in hematopoiesis, *DNM3* expression is restricted to the megakaryocytic lineage (Figure 2B; supplemental Figure 4). In other tissues, *DNM3* transcript is also found in brain, lung, heart, and testis (supplemental Figure 5A-B).^{8,9,29,30}

MEIS1 and variant rs2038479 co-occur in the proximity of a MK specific alternative *DNM3* transcription start site

In the *DNM3* gene locus, the MEIS1 binding event occurs very close to, although does not contain, variant rs2038479 (90 bp from MEIS1 peak maximum). This variant is 10 460 bp upstream and in strong linkage disequilibrium with the GWAS sentinel SNP rs10914144 ($r^2 = 0.991$ in Europeans; 1000 Genomes, June 2011 release). Both the MEIS1 binding site and variant rs2038479 lie at a

Figure 2. DN3 harbors MEIS1 binding sites and is associated with differences in MPV. (A) Co-occurrence of MPV and PLT count association SNPs with MEIS1 ChIP-seq peaks. (B) Transcript levels of DN3 genes during in vitro differentiation of MKs from human cord blood CD34⁺ cells, as measured by quantitative real-time RT-PCR (n = 3). Error bars represent SD. (C) MPV of the PLTs of persons according to genotype for sentinel SNP rs10914144 (n = 26 of 26). Mann-Whitney test: $P = .03$.



putative promoter of an alternative transcript *ENST0000523513* (termed alternative transcript hereafter) that is so far solely based on EST clones derived from CD34⁺ cells obtained from cord blood (AF150278 and AV739470). RNA-seq data for cultured MK revealed transcription surrounding rs2038479 (Figure 3B), suggesting a novel *DNM3* exon of ~ 133 bp (exon 2B hereafter). 5' RACE with RNA from cultured MKs, CHRF cells, and PLTs (Figure 3C) confirmed the expression of exon 2B and the presence of an alternative transcription start site. Furthermore, RACE analysis revealed that exons 1 and 2 are not part of the predominant *DNM3* transcript in MKs (see supplemental Table 2 for RACE clone sequences). Using primers in exon 2B and the annotated 3'-untranslated region, a PCR product was obtained from MK cDNA that contained an open reading frame extending from exon 2B to the annotated stop codon after Asp859 (data not shown).

Because the annotated *DNM3* consensus transcript is derived from human brain tissue, we quantified expression levels of both transcripts in cerebellum and MKs. This revealed a striking tissue specific expression pattern, with the consensus transcript being used in the former and the alternative one in the latter (Figure 4B). Indeed, expression of the alternative transcript appears restricted to the megakaryocytic lineage (supplemental Figures 5 and 6A-C), with the expression of this isoform substantially increasing during megakaryopoiesis (Figure 4C; supplemental Figure 6D).

Variant rs2038479 displays allelic differences in the promoter activity of the MK specific *DNM3* transcript

To test whether the variant affected *DNM3* expression, we typed the sentinel SNP rs10914144 in 5034 healthy volunteers from the Cambridge BioResource and recalled 2 groups of 26 persons homozygous for each allele. Typing of the samples for rs2038479 showed complete concordance in all but 1 sample from a person homozygous for the minor allele of rs10914144, which tested heterozygous for rs2038479. MPV and PLT *DNM3* RNA levels were compared between groups and, as expected, the minor allele was associated with lower MPV, consistent with the GWAS results derived from nearly 67 000 persons ($P = .03$; Figure 2C). Comparison of the PLT *DNM3* transcript levels with a probe specific for the alternative exon 2B revealed a statistically significant difference between groups, with lower levels in persons homozygous for the minor allele ($P = .0036$; Figure 4A). This difference was not observed with a probe specific for the consensus transcript ($P = .9967$).

Luciferase reporter constructs for the consensus and alternative promoters confirmed the quantitative PCR data. Whereas the consensus promoter was active in both CHRF and 1603MED (a human medulloblastoma cell line) cells, the alternative one was exclusively active in CHRF cells (Figure 4D). We then tested the effect of the rs2038479 variant on the activity of the alternative promoter and observed reduced activity in CHRF cells with the minor versus the major allele (Figure 4D; $P = .002$), which is




Figure 3. The DNMT3 locus harbors a regulatory element and an alternative exon in annotated intron 2. (A) DNMT3 gene locus showing CEU LOD plot (HapMap release 22). (B) Close-up of gene region, including exons 1-4 with regional plots from FAIRE-seq, MEIS1 ChIP-seq, and RNA-seq data. Also depicted are key SNPs rs10914144 and rs2038479. (C) Further close-up of the region of the MEIS1 peak in intron 2 showing RNA-seq peak, sequence location of the longest 5'RACE clone, alternative transcript ENST00000523513, and 2 EST clones as well as position of variant rs2038479.

consistent with the allelic differences in PLT *DNMT3* transcript levels between the 2 genotype groups. Electrophoretic mobility shift assay with probes harboring alternative forms of rs2038479 incubated with CHRF nuclear lysates displayed a striking difference between the 2 alleles with strong band shifting for the minor allele, thus revealing preferential binding of nuclear factors to this allele (supplemental Figure 7). Taken together, these data strongly suggest that rs2038479 is the more likely causative variant underlying the observed association with MPV, resulting in increased binding of a repressor complex at this locus.

Loss of Dynamin activity results in impaired pro-PLT formation

We reasoned, because of the observed positive correlation between PLT *DNMT3* transcript levels and MPV (Figures 2C and 4A), that

inhibition of the DNMT proteins may exert an effect on the processes of megakaryopoiesis and pro-PLT formation. To test this, MKs were generated by culture of murine fetal liver cells in the presence and absence of Dynasore, an inhibitor of DNMT GTPase activity.³¹ The proportion of MKs that formed pro-PLT processes was recorded (Figure 5A) and compared between the treated and control cultures. A significant reduction was observed (Figure 5B), providing additional evidence for the importance of DNMT activity in this process.

Discussion

The volume and count of PLTs vary widely in the healthy population but are tightly regulated within narrow ranges at the individual level. The population variation in MPV and PLT is for a large extent genetically controlled. In a GWAS in nearly 67 000 persons of European ancestry, we identified 68 independent genetic loci associated with either or both PLT traits at GW significance.¹ The sentinel SNP of 54 of the loci mapped within 10 kb of a gene providing probable biologic candidate proteins. At 15 of the 54 loci, the sentinel SNP or a proxy SNP in high linkage disequilibrium ($r^2 > 0.8$) altered the amino acid sequence of the implicated protein, thus providing a plausible functional explanation for the observed associations. The sentinel SNPs at the 53 remaining loci are synonymous or noncoding ones, generally localized in introns or sometimes in intergenic regions and therefore are likely to exert their effect on megakaryopoiesis and the formation and survival of PLTs by regulating gene transcription, possibly through lineage-specific regulatory elements.²

Here we have presented a prioritization strategy to select genes and variants for functional follow-up studies to investigate their role in the megakaryocytic lineage based on only considering associated variants that are also located at MEIS1 binding sites. This has resulted in a small list of readily tractable loci of which we selected *DNMT3* for in-depth analysis.

A similar overlapping strategy has been adopted previously using regions of open chromatin as markers for regulatory elements as determined by FAIRE. For example, in Paul et al,² we used FAIRE-ChIP to identify potential regulatory variants and showed that the major (C) allele of the MPV variant rs342293 at 7q22.3 is bound by the transcription factor EVI1/MECOM more firmly than the minor (G) allele. Binding of EVI1/MECOM to the major allele at this position is likely to be associated with repression of transcription and results in a lower *PIK3CG* transcript level in persons homozygous for the major allele compared with those homozygous for the minor allele. Although the selection of EVI1/MECOM as likely candidate was based on computational prediction followed by experimental validation, the present study used in vivo transcription factor binding to prioritize potential regulatory variants.

To explore the mechanisms that underlie the observed associations between noncoding sequence variants and the PLT traits of volume and count, we chose to focus on the transcription factor *MEIS1*. In lineage-committed blood cells *MEIS1* is uniquely transcribed in megakaryocytic cells, and not in the other 7 major mature blood cell types (supplemental Figure 1).⁸ The functional role of *MEIS1* in hematopoiesis and leukemogenesis has been studied extensively,³²⁻³⁴ but its role in megakaryopoiesis and PLT formation has not yet been fully appreciated. In this study, we postulated that a fraction of the association SNPs identified by GWAS or their proxy SNPs may modify target




Figure 4. Identification of functional SNP rs2038479 in a novel, lineage-specific promoter. (A) Relative DNM3 transcript levels in PLTs from persons homozygous for the major or minor allele of variant rs2038479. Quantitative real-time RT-PCR results with a probe specific for the novel exon 2B-exon 3 boundary (left) versus the annotated exon 2-exon 3 boundary (right) ($n = 24/23$, unpaired t test, including Welch correction for unequal variances). (B) Relative transcript abundance of tissues as measured by quantitative PCR. MK indicates MK; EB, erythroblast; and CB, cerebellum. $n = 3$. Error bars represent SD, relative to annotated transcript day 0 = 1. (C) Quantitative PCR comparison of 2 major DNM3 transcripts during MK maturation ($n = 3$). Error bars represent SD, relative to annotated transcript day 0 = 1. (D) In vitro dual Luciferase reporter assay of promoter activity of the region 5' of alternative exon 2B, including variant rs2038479 compared with the consensus promoter 5' of exon 1. Left: Megakaryocytic CHRF cells. Right: Medulloblastoma cells 1603MED, relative to empty firefly vector = 100%. Error bars represent SD. The significance of the effect of the variant at the alternative promoter ($P = .002$) was determined using a linear mixed model based on 3 independent experiments with 3 replicates per experiment.

gene transcription via the transcription factor MEIS1 or one of its binding partners.

The first step in exploring this notion was to establish a comprehensive catalog of genes regulated by *MEIS1*. For this, we performed a ChIP-seq experiment in the megakaryocytic cell line CHRF. This revealed *MEIS1* binding events in a set of 1285 genes (Figure 1A-B), and this gene set showed a number of highly

significant and interesting features. First, the set was strongly enriched for the terms relevant to megakaryopoiesis and PLT biology (Table 1). Second, there was an excess of genes, which are relatively overexpressed in MKs compared with the other 7 mature blood cell elements (Figure 1B; $P < 5 \times 10^{-19}$). Furthermore, 6 of the 57 MK overexpressed genes (*ABCC4*, *DNM3*, *LRRC16A*, *PDIA5*, *TPM4*, and *ZFPM2*) harbored a sentinel GWAS SNPs




Figure 5. Inhibition of dynamin in MK cultures. (A) Representative phase-contrast photomicrographs from the 2 treatments shown. DMSO was used at 0.3% final, Dynasore at 100 μ M final (taken with a 20 \times objective). Bar represents 50 μ m. (B) The proportion of murine MK developing pro-PLTs after 4 days culture of fetal liver cells, quantified as stated in "Methods."

(Figure 1B). Finally, the GW prioritization through co-occurrence of MEIS1 binding events with association SNPs identified 4 of the latter 6 genes plus SNP rs342293 at 7q22.3. Thus, not only did GW profiling of MEIS1 binding sites support the assumption that MEIS1 has an important role in conferring the PLT its cellular identity, but it also supported our assumption that allelic alteration of gene regulation by MEIS1 or its binding partners is possibly responsible for the observed associations with MPV and PLT at 5 GWAS loci.

We selected the *DNM3* gene on chromosome 1 of these 5 GWAS loci for further functional studies. The gene spans 571 kb, has 21 exons, and is the single gene in the recombination interval that harbored the PLT-volume sentinel SNP rs10914144. We therefore reasoned that either the sentinel SNP or one of its proxy SNPs was highly likely to regulate the transcription of the *DNM3* gene itself and not one of the other more distantly removed cis-positioned genes. Indeed, the analysis of 3 new GW datasets (Figure 3B-C) confirmed this assumption. It showed that SNP rs2038479, one of the proxy SNPs of the sentinel SNP, co-occurs with the MEIS1 binding event in the second intron of the *DNM3* locus. The FAIRE analysis showed that this SNP is at a position of open chromatin in CHRF cells (Figure 3B), which is absent in the erythroid K562 cell line (data not shown). The lineage-restricted open chromatin signature around SNP rs2038479 together with the presence of a MEIS1 binding event and already published ChIP-seq datasets from MKs³⁵ is strongly suggestive of a regulatory element specific for the MK lineage at this position (see supplemental Figure 8). Indeed, the sequencing of RNA from MKs showed that the same region is transcribed (Figure 3B), and suggested that the first 2 exons were transcribed at much lower levels. The presence of an alternative transcription start site and *DNM3* transcript with exon 2B as a first exon was confirmed by 5'RACE analysis and by quantitative PCR tests with transcript specific probes (Figure 4B; supplemental Figures 5 and 6). Moreover, we showed that the levels of the alternative transcript increase sharply during megakaryopoiesis (Figure 4C).

A recall study of persons from the Cambridge BioResource was used to compare the levels of the alternative *DNM3* transcript in PLTs between 2 groups of volunteers each, homozygous for the

major ($n = 24$) and minor alleles ($n = 23$) of rs10914144 and rs2038479, respectively. Both the MPV and RNA levels between the groups differed significantly (Figures 2C and 4A), indicating that the minor allele dictates lower levels of the *DNM3* transcript and these reduced levels are possibly causative of the formation of smaller PLTs. This in vivo observation was corroborated by the results of Luciferase-reporting assays, which revealed a significant lower signal in CHRF cells for the reporter construct containing the minor allele compared with the signal produced by the same construct harboring the major allele (Figure 4D). If rs2038479 is indeed the causative variant, this variant would have been expected to have a lower P value in the GWAS. Closer inspection of the meta-analysis revealed that rs2038479 ($P = 2.6 \times 10^{-22}$ for association with MPV) was genotyped or imputed in a smaller number of samples than rs10914144, consequently resulting in a higher P value.

DNM3 is a member of the dynamin family of large GTPases that each contain an amino-terminal GTPase domain, 3 central domains (middle, pleckstrin homology, and coiled coil) involved in self-assembly and membrane binding, and a carboxy-terminal proline-rich domain that links to SH3 domain-containing signaling/cytoskeletal partner proteins.³⁶ The dynamins have been shown to mediate endocytosis of clathrin-coated pits, vesicle budding, and pseudopodia formation.³⁷⁻⁴⁰ The *DNM3* protein has been observed immunochemically in human MK and murine pro-PLTs.³⁰ Interestingly, silencing of the *DNM3* gene in human CD34⁺ hematopoietic precursor cells seems to impair the formation of MKs, although this is possibly caused by the absence of the consensus *DNM3* protein in precursor cells.⁴¹ Here we provide evidence that pharmacologic inhibition of dynamin GTPase activity inhibits pro-PLT formation (Figure 5).

In conclusion, we have obtained evidence that 5 of the 68 GWAS SNPs for PLT count and volume are colocalized with a MEIS1 binding event. By focusing on one of these sites, we provide strong evidence that variant rs2038479 in the *DNM3* locus is the functionally causative allele, which underlies the observed association with PLT volume, controlling a MK-specific alternative promoter of the *DNM3* gene involved in PLT formation. Importantly, expression levels and promoter activity




Figure 6. From a PLT volume, GWAS variant at rs10914144 in the *DNM3* locus to the discovery of the functional variant rs2038479 at a MEIS1/RUNX1 binding site. A schema depicting the transcription of the *DNM3* gene at 1q24.3 in CD34+ hematopoietic stem cells (top panel) and in MKs (bottom panel), respectively. A GWAS identified variant rs10914144 in intron 2 as being associated with differences in MPV. The MPV of persons homozygous for the major (C) allele of the variant is higher compared with the values observed in persons who are homozygous for the minor (T) allele. Functional annotation of the genome of megakaryocytic cells identified binding sites for the transcription factor MEIS1 in intron 2 at a position of an alternative transcription start site, which is uniquely used in MKs. The same element harbors SNP rs2038479, which is in high linkage disequilibrium with the GWAS sentinel rs10914144. *DNM3* transcript levels (represented by the sizes of arrows at the consensus and alternative promoters) in PLTs from persons homozygous major (T) for rs2038479 were significantly lower than in PLTs from homozygous minor ones (C).

of the MK transcript are significantly and concordantly associated with the genotype of the original GWAS association SNP (rs10914144) and its proxy variant rs2038479, which resides at a MEIS1 binding site and marks the position of the alternative promoter. A schema showing the 2 SNPs and their relationship to *DNM3* gene transcription and PLT volume is shown in Figure 6. Further studies are required to define the functional role of the

alternative *DNM3* transcript in megakaryopoiesis and PLT formation.

Acknowledgments

The authors thank the volunteers of the Cambridge BioResource.

This work was supported in part by the National Institute for Health Research (program grant RP-PG-0310-1002; S.T.N., P.A.S., and W.H.O.), the British Heart Foundation (RG/09/12/28096; A.R.), and the Wellcome Trust (project grant WT-084183/2/07/2; J.G.S.). The Cambridge BioResource, a local resource for genotype-phenotype association studies, is supported by the National Institute for Health Research to the Cambridge Biomedical Research Center (J.G.S. and H.L.-J.). D.S.P. and K.V. were supported by the Marie-Curie NetSim ITN (grant EC-215820). M.R.T. was supported by a Marie-Curie Intra-European Fellowship (237296). The mouse study was supported in part by the National Institutes of Health (grant HL68130; J.E.I.). J.E.I. is an American Society of Hematology Junior Faculty Scholar. J.N.T. is an American Society of Hematology Scholar.

Authorship

Contribution: D.S.P., J.E.I., J.N.T., P.A.S., and S.T.N. designed and performed experiments and analyzed the data; A.R. analyzed the data; K.V., M.R.T., H.L.-J., and J.G.S. provided samples; N.S. provided data; P.D. and B.G. supervised experiments; W.H.O. supervised the project; and A.R., P.A.S., S.T.N., and W.H.O. wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

A list of the HaemGen Consortium members is provided in the online supplemental Appendix.

Correspondence: Willem H. Ouwehand, Department of Haematology, University of Cambridge, Cambridge, United Kingdom; e-mail: who1000@cam.ac.uk.

References

- Gieger C, Radhakrishnan A, Cvejic A, et al. New gene functions in megakaryopoiesis and platelet formation. *Nature*. 2011;480(7376):201-208.
- Paul DS, Nisbet JP, Yang T-P, et al. Maps of open chromatin guide the functional follow-up of genome-wide association signals: application to hematological traits. *PLoS Genet*. 2011;7(6):e1002139.
- Moskow JJ, Bullrich F, Huebner K, Daar IO, Buchberg AM. Meis1, a PBX1-related homeobox gene involved in myeloid leukemia in BXH-2 mice. *Mol Cell Biol*. 1995;15(10):5434-5443.
- Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. *Mol Cell Biol*. 2001;21(1):224-234.
- Pineault N, Buske C, Feuring-Buske M, et al. Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. *Blood*. 2003;101(11):4529-4538.
- Heuser M, Yun H, Berg T, et al. Cell of origin in AML: susceptibility to MN1-induced transformation is regulated by the MEIS1/AbdB-like HOX protein complex. *Cancer Cell*. 2011;20(1):39-52.
- Wilson NK, Foster SD, Wang X, et al. Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. *Cell Stem Cell*. 2010;7(4):532-544.
- Watkins NA, Gusnanto A, de Bono B, et al. A HaemAtlas: characterizing gene expression in differentiated human blood cells. *Blood*. 2009;113(19):e1-e9.
- Novershtern N, Subramanian A, Lawton LN, et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. *Cell*. 2011;144(2):296-309.
- Azcoitia V, Aracil M, Martinez AC, Torres M. The homeodomain protein Meis1 is essential for definitive hematopoiesis and vascular patterning in the mouse embryo. *Dev Biol*. 2005;280(2):307-320.
- Hisa T, Spence SE, Rachel RA, et al. Hematopoietic, angiogenic and eye defects in Meis1 mutant animals. *EMBO J*. 2004;23(2):450-459.
- Cvejic A, Serbanovic-Canic J, Stemple DL, Ouwehand WH. The role of meis1 in primitive and definitive hematopoiesis during zebrafish development. *Haematologica*. 2011;96(2):190-198.
- Pillay LM, Forrester AM, Erickson T, Berman JN, Waskiewicz AJ. The Hox cofactors Meis1 and Pbx act upstream of gata1 to regulate primitive hematopoiesis. *Dev Biol*. 2010;340(2):306-317.
- Fugman DA, Witte DP, Jones CL, Aronow BJ, Lieberman MA. In vitro establishment and characterization of a human megakaryoblastic cell line. *Blood*. 1990;75(6):1252-1261.
- Raso A, Negri F, Gregorio A, et al. Successful isolation and long-term establishment of a cell line with stem cell-like features from an anaplastic medulloblastoma. *Neuropathol Appl Neurobiol*. 2008;34(3):306-315.
- Macaulay IC, Tijssen MR, Thijssen-Timmer DC, et al. Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins. *Blood*. 2007;109(8):3260-3269.
- Lunter G, Goodson M. Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads. *Genome Res*. 2011;21(6):936-939.
- Zhang Y, Liu T, Meyer CA, et al. Model-based analysis of ChIP-Seq (MACS). *Genome Biol*. 2008;9(9):R137-R137.
- Mercier E, Droit A, Li L, Robertson G, Zhang X, Gottardo R. An integrated pipeline for the genome-wide analysis of transcription factor binding sites from ChIP-Seq. *PLoS One*. 2011;6(2):e16432.
- Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. *Nature*. 2007;449(7164):851-861.

21. McLean CY, Bristor D, Hiller M, et al. GREAT improves functional interpretation of cis-regulatory regions. *Nat Biotechnol*. 2010;28(5):495-501.
22. Al-Shahrour F, Minguez P, Vaquerizas JM, Conde L, Dopazo J. BABELOMICS: a suite of web tools for functional annotation and analysis of groups of genes in high-throughput experiments. *Nucleic Acids Res*. 2005;33(Web Server issue):W460-W464.
23. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc*. 1995;57:289-300.
24. Giresi PG, Kim J, McDaniel RM, Iyer VR, Lieb JD. FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) isolates active regulatory elements from human chromatin. *Genome Res*. 2007;17(6):877-885.
25. Thon JN, Montalvo A, Patel-Hett S, et al. Cytoskeletal mechanics of proplatelet maturation and platelet release. *J Cell Biol*. 2011;191(4):861-874.
26. Soranzo N, Spector TD, Mangino M, et al. A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. *Nat Genet*. 2009;41(11):1182-1190.
27. Obar RA, Collins CA, Hammarback JA, Shpetner HS, Vallee RB. Molecular cloning of the microtubule-associated mechanochemical enzyme dynamin reveals homology with a new family of GTP-binding proteins. *Nature*. 1990;347(6290):256-261.
28. Sontag JM, Fykse EM, Ushkaryov Y, Liu JP, Robinson PJ, Südhof TC. Differential expression and regulation of multiple dynamins. *J Biol Chem*. 1994;269(6):4547-4554.
29. Cao H, Garcia F, McNiven MA. Differential distribution of dynamin isoforms in mammalian cells. *Mol Biol Cell*. 1998;9(9):2595-2609.
30. Reems JA, Wang W, Tsubata K, et al. Dynamin 3 participates in the growth and development of megakaryocytes. *Exp Hematol*. 2008;36(12):1714-1727.
31. Macia E, Ehrlich M, Massol R, Boucrot E, Brunner C, Kirchhausen T. Dynasore, a cell-permeable inhibitor of dynamin. *Dev Cell*. 2006;10(6):839-850.
32. Woolthuis CM, Han L, Verkaik-Schakel RN, et al. Downregulation of MEIS1 impairs long-term expansion of CD34(+) NPM1-mutated acute myeloid leukemia cells. *Leukemia*. 2012;26(4):848-53.
33. Orlovsky K, Kalinkovich A, Rozovskaia T, et al. Down-regulation of homeobox genes MEIS1 and HOXA in MLL-rearranged acute leukemia impairs engraftment and reduces proliferation. *Proc Natl Acad Sci U S A*. 2011;108(19):7956-7961.
34. Argiropoulos B, Yung E, Xiang P, et al. Linkage of the potent leukemogenic activity of Meis1 to cell-cycle entry and transcriptional regulation of cyclin D3. *Blood*. 2010;115(20):4071-4082.
35. Tijssen MR, Cvejic A, Joshi A, et al. Genome-wide analysis of simultaneous gata1/2, runx1, flil1, and scl binding in megakaryocytes identifies hematopoietic regulators. *Dev Cell*. 2011;20(5):597-609.
36. Praefcke GJ, McMahon HT. The dynamin superfamily: universal membrane tubulation and fission molecules? *Nat Rev Mol Cell Biol*. 2004;5(2):133-147.
37. Henley JR, Krueger EW, Oswald BJ, McNiven MA. Dynamin-mediated internalization of caveolae. *J Cell Biol*. 1998;141(1):85-99.
38. Oh P, McIntosh DP, Schnitzer JE. Dynamin at the neck of caveolae mediates their budding to form transport vesicles by GTP-driven fission from the plasma membrane of endothelium. *J Cell Biol*. 1998;141(1):101-114.
39. van der Blik AM, Redelmeier TE, Damke H, Tisdale EJ, Meyerowitz EM, Schmid SL. Mutations in human dynamin block an intermediate stage in coated vesicle formation. *J Cell Biol*. 1993;122(3):553-563.
40. McNiven MA, Kim L, Krueger EW, Orth JD, Cao H, Wong TW. Regulated interactions between dynamin and the actin-binding protein cortactin modulate cell shape. *J Cell Biol*. 2000;151(1):187-198.
41. Wang W, Gilligan DM, Sun S, Wu X, Reems J-A. Distinct functional effects for dynamin 3 during megakaryocytopoiesis. *Stem Cells Dev*. 2011;20(12):2139-2151.